<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8061218</article-id><article-id pub-id-type="publisher-id">8195</article-id><article-id pub-id-type="doi">10.1186/s12885-021-08195-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bahig</surname><given-names>Houda</given-names></name><address><email>Houda.bahig.chum@ssss.gouv.qc.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rosenthal</surname><given-names>David I.</given-names></name><address><email>dirosenthal@mdanderson.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen-Tan</surname><given-names>F&#x000e9;lix-Phuc</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fuller</surname><given-names>David C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hutcheson</surname><given-names>Katherine A.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Christopoulos</surname><given-names>Apostolos</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nichols</surname><given-names>Anthony C.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fung</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ballivy</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Filion</surname><given-names>Edith</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Sweet Ping</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Lambert</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Dorth</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Kenneth S.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Palma</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.410559.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0743 2111</institution-id><institution>Radiation Oncology Department, </institution><institution>Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al, </institution></institution-wrap>1051 Sanguinet, Montreal, QC H2X 3E4 Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Radiation Oncology Department, </institution><institution>University of Texas MD Anderson Cancer Center, </institution></institution-wrap>1515 Holcombe, Houston, TX 77030 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Biostatistics Department, </institution><institution>University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Head and Neck Surgery Department, </institution><institution>University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.410559.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0743 2111</institution-id><institution>Head and Neck Surgery Department, </institution><institution>Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al, </institution></institution-wrap>Montreal, Canada </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.39381.30</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8884</institution-id><institution>Department of Otolaryngology - Head and Neck Surgery, </institution><institution>Western University, </institution></institution-wrap>London, Ontario Canada </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.1055.1</institution-id><institution-id institution-id-type="ISNI">0000000403978434</institution-id><institution>Radiation Oncology Department, </institution><institution>Peter MacCallum Cancer Centre, </institution></institution-wrap>Melbourne, Australia </aff><aff id="Aff8"><label>8</label>Radiation Oncology Department, Centre Int&#x000e9;gr&#x000e9; de Canc&#x000e9;rologie de Laval, Laval, Canada </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.67105.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2164 3847</institution-id><institution>Radiation Oncology Department, </institution><institution>Case Western Reserve University, </institution></institution-wrap>Cleveland, USA </aff><aff id="Aff10"><label>10</label>Radiation Oncology Department, NYU Langone Health, Newyork, USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.39381.30</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8884</institution-id><institution>Radiation Oncology Department, </institution><institution>Western University, </institution></institution-wrap>London, Ontario Canada </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>4</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>4</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>21</volume><elocation-id>446</elocation-id><history><date date-type="received"><day>22</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Radiotherapy, along with laser surgery, is considered a standard treatment option for patients with early glottic squamous cell cancer (SCC). Historically, patients have received complete larynx radiotherapy (CL-RT) due to fear of swallowing and respiratory laryngeal motion and this remains the standard approach in many academic institutions. Local control (LC) rates with CL-RT have been excellent, however this treatment can carry significant toxicities include adverse voice and swallowing outcomes, along with increased long-term risk of cerebrovascular morbidity. A recent retrospective study reported improved voice quality and similar local control outcomes with focused vocal cord radiotherapy (VC-RT) compared to CL-RT. There is currently no prospective evidence on the safety of VC-RT. The primary objective of this Bayesian Phase II trial is to compare the LC of VC-RT to that of CL-RT in patients with T1N0 glottic SCC.</p></sec><sec><title>Methods</title><p id="Par2">One hundred and fifty-five patients with T1a-b N0 SCC of the true vocal cords that are n ot candidate or declined laser surgery, will be randomized in a 1:3 ratio the control arm (CL-RT) and the experimental arm (VC-RT). Randomisation will be stratified by tumor stage (T1a/T1b) and by site (each site will be allowed to select one preferred radiation dose regimen, to be used in both arms). CL-RT volumes will correspond to the conventional RT volumes, with the planning target volume extending from the top of thyroid cartilage lamina superiorly to the bottom of the cricoid inferiorly. VC-RT volumes will include the involved vocal cord(s) and a margin accounting for respiration and set-up uncertainty. The primary endpoint will be LC at 2-years, while secondary endpoints will include patient-reported outcomes (voice impairment, dysphagia and symptom burden), acute and late toxicity radiation-induced toxicity, overall survival, progression free survival, as well as an optional component of acoustic and objective measures of voice analysis using the Consensus Auditory-Perceptual Evaluation of Voice.</p></sec><sec><title>Discussion</title><p id="Par3">This study would constitute the first prospective evidence on the efficacy and safety of VC-RT in early glottic cancer. If positive, this study would result in the adoption of VC-RT as standard approach in early glottic cancer.</p></sec><sec><title>Trial registration</title><p id="Par4">ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03759431">NCT03759431</ext-link></p><p id="Par5">Registration date: November 30, 2018</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12885-021-08195-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Glottic cancer</kwd><kwd>Larynx</kwd><kwd>Radiotherapy</kwd><kwd>Vocal cord</kwd><kwd>Local control</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><sec id="Sec2"><title>Role of radiotherapy in early glottic cancer</title><p id="Par33">Each year, over 150,000 new cases of laryngeal cancer are diagnosed worldwide [<xref ref-type="bibr" rid="CR1">1</xref>] and over a thousand new cases are diagnosed in Canada [<xref ref-type="bibr" rid="CR2">2</xref>]. Treatment options for early stage laryngeal cancer (T1&#x02013;2N0) include transoral endoscopic microsurgery [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>], radical radiotherapy (RT) [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>] and, in rare cases, partial laryngectomy via open surgery [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Whereas endoscopic microsurgery (with or without laser) typically involves resection of only the tumor-bearing vocal cord with a narrow 1&#x02013;2&#x02009;mm margin, current standard RT involves irradiation of the entire larynx [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Although prospective evidence comparing RT to surgery is lacking, both treatment options were reported to have equivalent oncological outcomes in terms of local control (LC) and overall survival (OS) in several meta-analysis [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>] and systematic reviews [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Radical RT outcomes for early glottic cancer are excellent with reported 5-year LC rates varying between 85 and 95% and 5-year OS exceeding 90% [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Although it is often suggested that RT is associated with better voice preservation compared to surgery, notably in larger tumors and tumors involving the anterior commissure [<xref ref-type="bibr" rid="CR26">26</xref>], this remains controversial [<xref ref-type="bibr" rid="CR19">19</xref>]. In a first meta-analysis including 8 retrospective cohort studies, although 2 studies reported improved voice preservation with RT, pooled results showed similar voice outcomes between transoral laser surgery and RT in T1 glottic cancers [<xref ref-type="bibr" rid="CR27">27</xref>]. In a more recent meta-analysis including 14 studies and comparing outcomes of surgery vs. RT for T1 glottis cancers, while subjective voice assessments were comparable, RT was associated with improved maximum phonation time and decreased fundamental frequency [<xref ref-type="bibr" rid="CR28">28</xref>]. Selection of optimal treatment modality currently involves institutional expertise and elicitation of patient preferences, and although substantiated by debatable evidence, also takes into account factors such as tumor size, location and histology [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. In a recent prospective study on the choice of treatment in patients with T1&#x02013;2N0 glottic cancer, it was reported while 51% of patients are oriented directly towards RT by the medical team (i.e. deemed not suitable for surgery), a third of patients offered either transoral laser surgery or RT opted for RT [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec3"><title>Toxicities of complete larynx radiotherapy</title><p id="Par34">Despite good LC, a substantial number of patients treated with radical RT experience persistent voice impairment after treatment [<xref ref-type="bibr" rid="CR33">33</xref>]. Several studies have reported mild-to-moderate voice impairments after early glottic cancer RT in the acute, subacute and chronic settings [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. There is currently limited data on threshold doses for functional voice preservation and, in the context of current RT fields, this has been of little pertinence considering that the entire larynx would receive the full dose, leaving little room for organs at risk sparing. Dornfeld et al. [<xref ref-type="bibr" rid="CR37">37</xref>] found a strong correlation between quality of speech and doses to various structures of the glottic and supraglottic larynx as well as the pharyngeal walls. Available dose-volume data suggest that mean dose to the larynx above 45&#x02009;Gy and mean dose to the non-involved vocal cord above 50&#x02009;Gy are predictors of grade&#x02009;&#x02265;&#x02009;2 laryngeal oedema and worse voice outcomes [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par35">Other common toxicities of larynx RT for early glottic cancer include increased risk of carotid artery stenosis and hypothyroidism. Cerebrovascular morbidity from carotid artery stenosis has been documented in several studies in the setting of conventional RT [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. In a recent SEER-database study, RT for treatment of early glottic cancer was associated with an increased risk of mortality due to cerebrovascular events in comparison to surgery [<xref ref-type="bibr" rid="CR42">42</xref>]. Doses to the carotids between 35 and 50&#x02009;Gy have been associated with carotid vessels wall thickening [<xref ref-type="bibr" rid="CR43">43</xref>]. In addition, rates of radiation-induced hypothyroidism vary between 13 and 47% [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], with highest frequency at 1&#x02009;year after treatment. Other severe toxicities of larynx RT include less than 1% risk of permanent tracheostomy due persistent laryngeal oedema and loss of functional larynx [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] and less than 1% risk of persistent mild or moderate dysphagia [<xref ref-type="bibr" rid="CR46">46</xref>]. Importantly, laryngeal cancer patients have 22% risk of developing a secondary malignancy, with the wide majority originating from the upper aero-digestive tract [<xref ref-type="bibr" rid="CR47">47</xref>]. In this context, their previous history of complete larynx RT limits their future therapeutic options.</p></sec><sec id="Sec4"><title>Complete larynx radiation field and larynx motion</title><p id="Par36">The historical standard for early glottic cancer remains the use of 3D-conformal radiotherapy, most commonly using lateral opposing fields, with field size of 5&#x02009;&#x000d7;&#x02009;5&#x02009;cm<sup>2</sup> to 6&#x02009;&#x000d7;&#x02009;6&#x02009;cm<sup>2</sup> [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] centered on the thyroid cartilage. Typically, the superior, posterior, inferior and anterior borders of the field are 0.5&#x02013;1.0&#x02009;cm above the thyroid notch, 1&#x02009;cm behind the thyroid cartilage, below the cricoid and 1&#x02009;cm beyond the patient&#x02019;s external contour, respectively [<xref ref-type="bibr" rid="CR13">13</xref>]. Although the use of intensity modulated radiotherapy (IMRT) for early glottic cancer remains controversial, several institutions have adopted carotid-sparing IMRT planning [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Clinical outcomes from complete larynx IMRT was published by the Memorial Sloan-Kettering Cancer Center and showed excellent 3&#x02009;years LC [<xref ref-type="bibr" rid="CR15">15</xref>]. The margins used in complete larynx IMRT remain conservative because of fear of geographical miss associated with internal motion of the larynx such as swallowing or breathing.</p><p id="Par37">Although swallowing motion is associated with large larynx excursion up to 2&#x02009;cm in the superior direction [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>], swallowing motion was reported to be rare, rapid and easily suppressed by patients, and is therefore considered to have negligible impact on RT dose delivery [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. Although precaution should be taken to ensure that the planning CT is not acquired while the patient is swallowing (to avoid a risk of systematic error throughout treatment), additional margins to account for swallowing motion appear unnecessary [<xref ref-type="bibr" rid="CR50">50</xref>]. On the other hand, respiratory motion in the order of several millimetres has also been described [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Respiratory motion reaching 6&#x02009;mm in the superior-inferior direction and 2&#x02009;mm in the antero-posterior direction has previously been described [<xref ref-type="bibr" rid="CR50">50</xref>]. Such intra-fraction motion cannot be addressed by means of daily image guidance and can be associated with a risk of tumor miss in the context of tighter treatment margin. In addition, occurrence of a larynx shift in relation to the vertebral structures, potentially resulting from anatomical changes over time or set-up reproducibility, has also been described [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. The latter finding stresses the importance of daily imaging with laryngeal match rather than bone match if tight margins are considered.</p></sec><sec id="Sec5"><title>Vocal-cord only irradiation</title><p id="Par38">In recent years, increasing interest in reducing RT treatment volumes has emerged, with the objective of reducing toxicity while maintaining LC. In fact, in the era of IMRT and image-guided radiotherapy (IGRT), it is appealing to mirror surgical approaches and evaluate vocal-cord radiotherapy (VC-RT). Focal vocal cord RT for T1N0 glottic cancer has been assessed in dosimetric studies which confirmed adequate target volume coverage [<xref ref-type="bibr" rid="CR58">58</xref>], homogeneity of planning target volume (PTV) coverage [<xref ref-type="bibr" rid="CR50">50</xref>], as well as sparing of various laryngeal structures (including the contralateral vocal cord and arytenoid), the carotids and thyroid gland compared to conventional RT [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. The group from Erasmus Medical Center Cancer has reported clinical outcomes from a retrospective analysis of 30 patients with T1aN0 glottic cancer treated with VC-RT [<xref ref-type="bibr" rid="CR35">35</xref>]. They reported excellent 2&#x02009;year LC of 100% as well as lower rates of acute toxicities and improved voice outcomes compared to a similar cohort of patients treated with CL-RT [<xref ref-type="bibr" rid="CR35">35</xref>]. In fact, VC-RT was associated with clinically significant voice preservation compared to CL-RT immediately after RT, at 6&#x02013;12&#x02009;weeks and at 6&#x02013;12-18&#x02009;months after RT [<xref ref-type="bibr" rid="CR36">36</xref>]. By maximally avoiding structures involved in voice preservation, VC-RT has the potential to reduce the rate and severity of acute and chronic toxicities and minimize voice impairment, while maintaining current excellent local control rates. While some institutions have adopted a partial larynx RT approach in early glottic cancer, there is currently no prospective evidence on efficacy or safety of VC-RT and many academic institutions continue to consider treating the entire larynx as standard of care. The hypothesis of the current phase II study is that VC-RT would lead to non-inferior LC compared to historical outcomes of CL-RT in patients with T1N0 glottic cancer.</p></sec></sec><sec id="Sec6"><title>Methods/design</title><sec id="Sec7"><title>Study objectives</title><p id="Par39">The objective of this trial is to assess the efficacy and safety of VC-RT, compared to CL-RT, in T1N0 glottic squamous cell carcinoma.</p><p id="Par40">Primary endpoint:
<list list-type="bullet"><list-item><p id="Par41">Local control at 2-year after the end of RT.</p></list-item></list></p><p id="Par42"><italic>Local control will be defined as absence of biopsy proven recurrence within the larynx.</italic></p><p id="Par43">Secondary endpoints:
<list list-type="bullet"><list-item><p id="Par44">Patient-reported outcomes including dysphagia, voice impairment, and symptom burden.</p></list-item><list-item><p id="Par45">Acute and late toxicity radiation-induced toxicity</p></list-item><list-item><p id="Par46">OS and progression free survival (PFS)</p></list-item><list-item><p id="Par47">Acoustic and objective measures of voice analysis using the Consensus Auditory-Perceptual Evaluation of Voice.</p></list-item></list></p></sec><sec id="Sec8"><title>Study design</title><p id="Par48">We propose a phase II, multicentre Bayesian trial. A total of 155 patients will be randomized in a 1:3 ratio to CL-RT (39 patients) or VC-RT (116 patients). Patients will be stratified by tumor stage (T1a/T1b) and by site (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). This study, which is registered on clinicaltrials.gov (NCT03759431), will include tertiary, academic hospitals in Canada and the United States. One dose and fractionation regimen will be determined by each participating center and will have to be the same in both arms. The study is powered to compare LC of VC-RT compared to historical outcomes of CL-RT. The purpose of the randomization will be to generate data on secondary outcomes of voice impairment, dysphagia and quality of life as well as survival outcomes in the control arm.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Study Scheme of the VOCAL Trial. N&#x02009;=&#x02009;Number of patients</p></caption><graphic xlink:href="12885_2021_8195_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec9"><title>Conditions for patient eligibility</title><p id="Par49">
<list list-type="bullet"><list-item><p id="Par50">Age&#x02009;&#x0003e;&#x02009;18&#x02009;years</p></list-item><list-item><p id="Par51">Stage T1a-b N0 of the true vocal cords planned for definitive RT</p></list-item><list-item><p id="Par52">Patient not candidate for laser surgery or declined laser surgery</p></list-item><list-item><p id="Par53">Biopsy-confirmed squamous cell carcinoma, including verrucous carcinoma</p></list-item><list-item><p id="Par54">Eastern Cooperative Oncology Group (ECOG) performance status 0&#x02013;2</p></list-item><list-item><p id="Par55">Ability to provide written informed consent.</p></list-item><list-item><p id="Par56">Ability to understand and read English or French at a level adequate for completion of patient reported outcomes questionnaires</p></list-item></list></p></sec><sec id="Sec10"><title>Conditions for patient ineligibility</title><p id="Par57">
<list list-type="bullet"><list-item><p id="Par58">Previous irradiation of the head and neck region</p></list-item><list-item><p id="Par59">Pregnancy or breastfeeding</p></list-item><list-item><p id="Par60">Any medical condition that represents, in the opinion of the investigator, a contraindication to radiotherapy or would prevent follow-up after radiotherapy.</p></list-item><list-item><p id="Par61">Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2&#x02009;years.</p></list-item></list></p></sec><sec id="Sec11"><title>Required pre-treatment evaluation</title><p id="Par62">
<list list-type="bullet"><list-item><p id="Par63">History and Physical Examination, including:
<list list-type="bullet"><list-item><p id="Par64">&#x000b0; Laryngoscopy, with detailed diagram of the primary lesion confirmed by both the radiation oncologist and head and neck surgeon</p></list-item><list-item><p id="Par65">&#x000b0; Biopsy of the primary tumor</p></list-item></list></p></list-item><list-item><p id="Par66">Patient reported outcomes questionnaires including the Voice Handicap Index 10 (VHI-10), the MD Anderson Dysphagia Inventory (MDADI) and the MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN).</p></list-item></list></p></sec><sec id="Sec12"><title>Intervention</title><p id="Par67">In both treatment arms, patients will be treated with a radical course of radiotherapy using a standard mild hypofractionation regimen of 5 fractions per week, over 4 to 6&#x02009;weeks. For pragmatic reasons, each participating institution is allowed to use their standard of care dose and fractionation, but will have to be identical between the standard and experimental arms at each institution. Each center will provide, at time study entrance, what dose and fractionation will be used. This dose and fractionation will be the same for both arms and cannot change over the course of the study. The study is stratified by participating institution, which means that it will be stratified by dose/fractionation. In both treatment arms, a daily volumetric imaging method will be required for set-up verification, with match on the larynx.</p><sec id="Sec13"><title>Immobilization and simulation</title><p id="Par68">Patients will be positioned in a comfortable and reproducible position and will be immobilized in a thermoplastic mask of the head and shoulders fixed to the treatment Table. A 3-dimensional planning computed tomography (CT) scan (maximum slice thickness of 1.5&#x02009;mm) of the neck will be obtained. A planning magnetic resonance imaging (MRI), co-registered to the planning CT to help define gross tumor volume (GTV), is recommended but optional.</p><p id="Par69">Clinicians should be aware of the risk of swallowing during CT simulation. Patients should be instructed not to swallow during the planning CT and MRI, as well as during their radiation treatment. Co-registration of the planning CT with a complementary planning volumetric imaging (such as MRI or contrast-enhanced CT) should be performed in order to verify the position of the larynx. If only one simulation imaging is obtained at time of planning, the position of the larynx should be verified on the first fraction of radiotherapy using a volumetric imaging method allowing 3D image reconstruction (Ex: Cone beam CT, CT on rail, MR-Linac).</p></sec><sec id="Sec14"><title>Volumes</title><p id="Par70">The GTV will be the same for both CL-RT and VC-RT and will be based physical examination and imaging (planning CT +/&#x02212; MRI).</p><sec id="FPar1"><title>Standard arm (CL-RT)</title><p id="Par71">The RT volume in the standard arm is based on expected fields from conventional CL-RT volume, with the planning target volume (PTV) extending from the top of thyroid cartilage lamina superiorly, to the bottom of the cricoid inferiorly. The volumes below are defined to lead to traditional volumes from conventional CL-RT (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).
<list list-type="bullet"><list-item><p id="Par72">CTV<sub>CL-RT</sub>&#x000a0;=&#x02009;GTV plus a manual expansion superiorly to include the cranial arytenoid cartilage, inferiorly to include 1&#x02013;1.5&#x02009;cm below true vocal cords, anteriorly to include the anterior commissure, posteriorly to include posterior commissure and arytenoid cartilage.</p></list-item><list-item><p id="Par73">PTV <sub>CL-RT</sub>&#x000a0;=&#x02009;1&#x02009;cm circumferential expansion around CTV <sub>CL-RT</sub> in all directions, except posteriorly where the margin will be 0.5&#x02009;cm. As the PTV of CL-RT is based on previous fields of conventional RT, after the addition of a 1&#x02009;cm margin, the PTV <sub>CL-RT</sub> should extend to the top of the thyroid cartilage lamina superiorly and to the bottom of the cricoid inferiorly; alternatively, the PTV <sub>CL-RT</sub> should be manually expanded.</p></list-item></list><fig id="Fig2"><label>Fig. 2</label><caption><p>Examples of VC-RT volumes in axial and sagittal view showing for a patient with right T1a glottic cancer (LEFT) and for a patient with T1b glottis cancer (RIGHT). The entire involved vocal cord (in T1a) or both vocal cords (in T1b) form the CTV (red); the ITV formed by an isotropic margin of 6&#x02009;mm around the CTV (yellow) and the PTV is formed by additional 2&#x02009;mm margin (green)</p></caption><graphic xlink:href="12885_2021_8195_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="FPar2"><title>Experimental arm (VC-RT)</title><p id="Par74">The RT volume would include the entire ipsilateral vocal cord in stage T1a disease, or both vocal cords in T1b disease. An internal target volume (ITV) consisting in an isotropic 6&#x02009;mm margin will be added to account for respiratory motion. An additional margin of 2&#x02013;3&#x02009;mm margin will be added for setup uncertainty (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).
<list list-type="bullet"><list-item><p id="Par75">CTV<sub>VC-RT</sub>&#x000a0;=&#x02009;GTV plus a manual expansion to include the entire ipsilateral vocal cord in stage T1a disease, or both vocal cords in stage T1b disease. In cases where the GTV is not visualized, only a CTV (comprising the entire involved vocal cord in T1a or both vocal cords in T1b) will be contoured.</p></list-item><list-item><p id="Par76">An internal target volume (ITV) will be added and will consist in an isotropic margin of 6&#x02009;mm around the CTV<sub>VC-RT</sub> to account for respiratory motion.</p></list-item><list-item><p id="Par77">PTV <sub>VC-RT</sub>&#x000a0;=&#x02009;ITV plus a 2&#x02013;3&#x02009;mm margin. This is smaller than in Arm 1, because internal motion is already accounted for in the ITV.</p></list-item></list></p></sec></sec><sec id="Sec15"><title>Dosimetry</title><p id="Par78">Use of either IMRT or protons (passive scattering or intensity modulated proton therapy) will be mandatory for all plans. Treatment plans will be normalised so that 95% of the PTV volume be covered with the prescription dose. The maximal dose to the PTV cannot exceed 110% of the prescribed dose and the dose to 99% of PTV should be above 95% of the prescribed dose (D99&#x02009;&#x0003e;&#x02009;95% of prescribed dose). Heterogeneity correction will be required for dose calculation.</p></sec><sec id="Sec16"><title>Critical structures delineation and constraints</title><p id="Par79">Critical structures delineation will be based on previously published international consensus guidelines [<xref ref-type="bibr" rid="CR61">61</xref>]. The latter reference provides a detailed atlas of each structure and should be consulted for additional precisions. Anatomic boundaries are details in <italic>Supplementary material </italic><xref rid="MOESM1" ref-type="media">1</xref>.</p><sec id="FPar3"><title>Standard arm (CL-RT)</title><p id="Par80">
<list list-type="bullet"><list-item><p id="Par81">Spinal cord: Not more than 0.03&#x02009;cc of the planning organ at risk (PRV) exceeds 42&#x02009;Gy and not more than 0.03&#x02009;cc of the spinal cord receives &#x0003e;&#x02009;40&#x02009;Gy.</p></list-item><list-item><p id="Par82">Optimization of dose to other organs at risk (OAR) is not required. However, carotid-sparing is authorized.</p></list-item></list></p></sec><sec id="FPar4"><title>Experimental arm (VC-RT)</title><p id="Par83">
<list list-type="bullet"><list-item><p id="Par84">Spinal cord: Not more than 0.03&#x02009;cc of the PRV exceeds 42&#x02009;Gy and not more than 0.03&#x02009;cc of the spinal cord receives &#x0003e;&#x02009;40&#x02009;Gy.</p></list-item><list-item><p id="Par85">Additional dose specification goals that should not take priority over PTV coverage:
<list list-type="bullet"><list-item><p id="Par86">&#x000b0; Carotid arteries:
<list list-type="bullet"><list-item><p id="Par87">&#x025aa; T1a</p></list-item><list-item><p id="Par88">Ipsilateral carotid: Mean dose &#x0003c;&#x02009;35&#x02009;Gy</p></list-item><list-item><p id="Par89">Controlateral carotid: Mean dose &#x0003c;&#x02009;15&#x02009;Gy</p></list-item><list-item><p id="Par90">&#x025aa; T1b
<list list-type="bullet"><list-item><p id="Par91">Mean dose to carotids &#x0003c;&#x02009;35&#x02009;Gy</p></list-item></list></p></list-item></list></p></list-item><list-item><p id="Par92">&#x000b0; Supraglottic larynx: Mean dose &#x0003c;&#x02009;45&#x02009;Gy</p></list-item><list-item><p id="Par93">&#x000b0; Contralateral vocal cord: Mean dose &#x0003c;&#x02009;50&#x02009;Gy</p></list-item></list></p></list-item><list-item><p id="Par94">Doses to other organs should be minimized and documented.</p></list-item></list></p></sec></sec><sec id="Sec17"><title>IGRT</title><p id="Par95">A volumetric imaging method allowing 3D image reconstruction (Ex: Cone beam CT, CT on rail, MR-Linac) will be required daily for set-up verification. Additional images (e.g. confirmatory kV X-ray) may be used as supplemental verification. Larynx soft-tissue matching is required (as opposed to bony landmark [e.g. spine, base of skull] alignment).</p></sec></sec><sec id="Sec18"><title>Study assessments</title><p id="Par96">
<list list-type="bullet"><list-item><p id="Par97">There will be evaluation immediately post-treatment, as well as at 6, 12 and 24&#x02009;months post-treatment as part of the study. Other follow-ups will be as per institution standard of care, but suggested schedule of assessments detailed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> is encouraged.</p></list-item><list-item><p id="Par98">Alternate follow-ups between the head and neck surgeon and the radiation oncologist will be mandatory.</p></list-item><list-item><p id="Par99">Physical examination will involve flexible laryngoscopy or/and videostrobe or/and mirror examination with adequate visualisation of vocal cords.</p></list-item><list-item><p id="Par100">Clinical follow-up will involve documentation of LC and survival status as well as reporting of CTCAE V4.03 toxicities.</p></list-item><list-item><p id="Par101">Patients will be asked to fill patient-reported outcome questionnaires at baseline and at each visit, as detailed in Table <xref rid="Tab1" ref-type="table">1</xref>. The questionnaires will be administered in the following order: VHI-10, MDADI and MDASI-HN. The questionnaires could be filled in paper format, or online using the anonymized CASTOR EDC system. The questionnaires will not be reviewed during the study and will be analysed only at the pre-specified timepoints.</p></list-item><list-item><p id="Par102">There will be an <italic>optional</italic> assessment of acoustic and objective measures of voice analysis by a speech pathologist at baseline, immediately post-treatment and at 6&#x02009;months post treatment. The assessments will consist in a digital recording of a standard oral reading passage and a short monologue, which would later be analyzed for specific acoustic variables and microacoustic measures of the cycle-to-cycle variation of acoustic parameters (in frequency and intensity domains). The voice quality will be graded as per then GRBAS scale (grade, roughness, breathiness, asthenia, strain).</p></list-item></list><table-wrap id="Tab1"><label>Table 1</label><caption><p>Suggested Schedule of Assessments</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Pre-RT</th><th>End of RT</th><th>2mo<sup>a</sup></th><th>6mo</th><th>12 mo</th><th>24 mo</th><th>36mo<sup>a</sup></th><th>48mo<sup>a</sup></th><th>60mo<sup>a</sup></th></tr></thead><tbody><tr><td>History (including TIA or stroke) &#x00026; physical exam (including laryngoscopy)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Side effects</td><td/><td/><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>TSH<sup>a</sup></td><td>x</td><td/><td/><td/><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Questionnaire VHI &#x02212;10</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Questionnaire MDADI and MDASI-HN</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr></tbody></table><table-wrap-foot><p><italic>RT</italic> Radiotherapy, <italic>Mo</italic> months</p><p><sup>a</sup>Optional assessments</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec19"><title>Statistical considerations</title><p id="Par103">According to previous experience, expected LC after CL-RT is estimated to be 92% [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Assuming a non-inferiority margin of 8%, if LC in the VC-RT arm is &#x02265;84% at 2-years, we will deem the VC-RT arm acceptable. With a sample size of 111 patients, over 82% power will detect a margin difference of 8%, at a target significance level of 0.05 using a one-sided, exact binomial test (NCSS-PASS 2005). The purpose of the randomization will be to generate currently unavailable data on secondary outcomes of voice impairment, dysphagia and quality of life in the CL-RT arm. Considering a 5% attrition rate, 155 patients will be randomized in a 1:3 ratio to CL-RT (39 patients) and VC-RT (116 patients) arms. Patients will be stratified by stage (T1a/T1b) and by institution.</p><p id="Par104">An interim analysis will be conducted when 55 patients have a minimal follow-up of 6&#x02009;months. We will monitor the efficacy endpoint using the Bayesian optimal phase 2 (BOP2) design [<xref ref-type="bibr" rid="CR62">62</xref>]. Specifically, let <italic>n</italic> denote the interim sample size and <italic>N</italic> denote the maximum sample size. Let <italic>p</italic><sub><italic>eff</italic></sub> denote the probability of efficacy (response rate) and define the null hypothesis <italic>H</italic><sub>0</sub>&#x02009;:&#x02009;<italic>p</italic><sub><italic>eff</italic></sub>&#x02009;&#x0003c;&#x02009;0.84, representing that the treatment is inefficacious. We will stop enrolling patients and claim that the treatment is not promising if
<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathit{\Pr}\left({p}_{eff}\ge 0.84\mid data\right)&#x0003c;\lambda {\left(\frac{n}{N}\right)}^{\alpha }, $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mo mathvariant="italic">Pr</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi mathvariant="italic">eff</mml:mi></mml:msub><mml:mo>&#x02265;</mml:mo><mml:mn>0.84</mml:mn><mml:mo>&#x02223;</mml:mo><mml:mtext mathvariant="italic">data</mml:mtext></mml:mrow></mml:mfenced><mml:mo>&#x0003c;</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:msup><mml:mfenced close=")" open="("><mml:mfrac><mml:mi>n</mml:mi><mml:mi>N</mml:mi></mml:mfrac></mml:mfenced><mml:mi>&#x003b1;</mml:mi></mml:msup><mml:mo>,</mml:mo></mml:math><graphic xlink:href="12885_2021_8195_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>where <italic>&#x003bb;</italic> =0.95 and <italic>&#x003b1;</italic> =1 are design parameters optimized to minimize the chance of incorrectly claiming that an efficacious treatment is not promising (i.e., type II error) under the alternative hypothesis <italic>H</italic><sub>1</sub>&#x02009;:&#x02009;<italic>p</italic><sub><italic>eff</italic></sub>&#x02009;=&#x02009;0.92, while controlling the type I error rate at 0.05 (i.e., the chance of incorrectly claiming that an inefficacious treatment is promising is no more than 5%). Assuming a Beta (0.84,0.16) prior distribution for <italic>p</italic><sub><italic>eff</italic></sub>, if more than 10 patients among the 55 patients develop recurrences, the trial will be stopped in the interim analysis. Otherwise, the trial will be continued.</p></sec><sec id="Sec20"><title>Analytic plan</title><p id="Par105">A Bayesian regression model [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] will be used to compare the LC between the VC-RT and CL-RT arms at 2&#x02009;years. The LC and OS time will be defined from end of RT date. The following recurrences will be considered LC: in field, field margin and within larynx. Local recurrences will be biopsy-proven when possible. Competing events will include local recurrence, regional/distant recurrence and death prior to recurrence. LC will be estimated using both competing risk and Kaplan -Meier (KM) analysis. The analyses will be conducted using SAS and R software. A Cox multivariable regression analysis will be used to determine factors predictive of LC, PFS and OS. Chi-squared test or Fisher&#x02019;s exact test will be used to compare the difference in toxicity between arms. For the secondary endpoints of patient-reported outcomes (VHI-10, MDADI and MDASI-HN), trajectory trends of scores between/among arms over time will be explored using a generalized linear mixed model with a random effect of time. Appropriate adjustments for covariates will be considered.</p><p id="Par106">There will be two planned analysis: 1) an interim analysis and, 2) a final analysis. The interim analysis will be done after 55 patients on the experimental arm have a minimum follow-up of 6&#x02009;months. A short follow-up time of 6&#x02009;months was chosen for the interim analysis for safety (i.e. for early detection of local recurrence trends). The trial may be interrupted early if VC-RT is deemed not promising on interim analysis. The final analysis will performed 2&#x02009;years after accrual is completed.</p></sec><sec id="Sec21"><title>Data safety and monitoring board</title><p id="Par107">A data safety and monitoring board (DSMB) from the Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al will be responsible for assessing the safety data. The trial would be interrupted early if higher than expected rates of local recurrences are observed. The DSMB will review interim/cumulative evidence of study related safety, consider factors external to the study when relevant information becomes available and provide the sponsor a recommendation as to whether the study should: continue without change, be modified, suspended or terminated. The DSMB will assess the safety data twice a year. An interim analysis will be planned after the first 55 patients in the experimental arm have a 6-month follow-up. Using a Bayesian probabilistic model, the trial would be interrupted early if higher than expected rates of local recurrences are observed. As this trial involves only a reduction of RT treatment volumes, we do not expect any increase in toxicities in patients treated on the experimental arm.</p></sec><sec id="Sec22"><title>Subject discontinuation / withdrawal</title><p id="Par108">Patients may withdraw from the study prior to the completion of study related procedures for the following reasons:
<list list-type="bullet"><list-item><p id="Par109">Patient withdraws consent for participation. Subjects may voluntarily discontinue participation in the study at any time.</p></list-item><list-item><p id="Par110">It is deemed in the patient&#x02019;s best interest as determined by the attending/principal investigator.</p></list-item></list></p></sec><sec id="Sec23"><title>Consent and confidentiality</title><p id="Par111">All enrolled patients will be required to sign informed consent before study entry. The principal investigator, the co-investigators and the research nurses will gather and record all collected information in a research record. All information collected will remain strictly confidential to the extent permitted by law. In all research records, subjects will be identified by enrolment number.</p></sec><sec id="Sec24"><title>Protocol amendments and trial publication</title><p id="Par112">The protocol, the informed consent form, and any other written information to be given to subjects will be reviewed and approved by a properly constituted Institutional Review Board (IRB)/Research Ethics Board (REB), operating in accordance with federal laws and regulations. Any institution opening this study will obtain REB IRB/REB approval prior to local initiation. Any amendment to the study will be submitted for review by the IRB/REB before any changes are implemented unless required to eliminate immediate hazard to the study participants.</p><p id="Par113">The results of this trial will be reported in scientific publications as well as scientific conferences. Patients will not be indicated by name. The protocol, results from interim analysis and final results will be published in peer-reviewed journals.</p></sec></sec><sec id="Sec25"><title>Discussion</title><p id="Par114">Swallowing motion over the course of early glottic radiotherapy has been reported to be rare and unlikely to impact on dose delivery [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. However, respiratory motion, laryngeal shift in relation to the vertebral structures over the course of RT, as well as the occasional occurrence of swallowing motion at the time of simulation could introduce substantial treatment delivery inaccuracies [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. The safety of VC-RT may therefore be highly dependent on adequate precautions including the addition of an ITV margin accounting for breathing motion, use of volumetric IGRT with daily match on the larynx as well as verification of larynx resting position at time of planning CT scan acquisition. Following these principles, the group from Erasmus MC Cancer Institute reported excellent outcomes from VC-RT in a retrospective cohort 30 patients with T1a glottic cancer, with no local failures at 2&#x02009;years [<xref ref-type="bibr" rid="CR35">35</xref>]. More recently, Sher et al. reported outcomes from a phase I dose-escalation trial (50&#x02009;Gy in 15 escalated to 42.5&#x02009;Gy in 5 fractions) of VC-RT for Tis-T2N0 of the glottis, using an ITV derived from a 4D-CT [<xref ref-type="bibr" rid="CR65">65</xref>]. While the study reported acceptable early tolerability of the ultra-hypofractionated regimen with 7% rate of dose limiting grade 3&#x02013;4 toxicity, as high as 17% of patients (5 of 29) developed a local recurrence. A closer look at these 5 recurrences reveals that 3 were among 7 patients with T2 tumors (leading to a 43% local recurrence rate in T2N0), 1 occurred in a patient with a T1b lesion that was inaccurately delineated and resulted in a marginal miss, and 1 was in a previously understaged tumor which, in retrospect, was a T4 lesion. While these results are somewhat reassuring in regard to the safety of VC-RT for T1N0 glottic larynx, these recurrences certainly highlight the importance of careful staging and accurate clinical assessment of tumor extension when considering VC-RT, and certainly question the safety of this approach for T2 tumors. Total laryngectomy frequently constituting the salvage treatment option in the context of local recurrence after irradiation, the consequences of treatment failures can have severe impacts on patients&#x02019; quality of life and survival. Taken together, these considerations justify the current equipoise as to whether VC-RT can lead to similar efficacy as CL-RT in early glottic cancer.</p><p id="Par115">The current phase II multicenter Bayesian trial will accrue 155 patients with T1N0 glottic cancer, randomized to VC-RT versus CL-RT. The study is limited by the fact that it does not constitute a true randomized non-inferiority trial, but the feasibility of such a design is rendered impossible by the unrealistic necessary sample size of &#x0003e;&#x02009;2000 patients. Therefore, this trial would likely provide the best possible comparison between the 2 treatment arms. Local control at 2&#x02009;years has been selected as the primary endpoint as the majority of local recurrences occur within the first 2&#x02009;years after radiotherapy [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>], however, LC will continue to be monitored in the context of this trial up to 5&#x02009;years after radiotherapy. LC in the literature for T1N0 of the glottic larynx varies between 85 and 95% [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].; this variation is at least partly dependent on the distribution of T1a versus T1b in the cohorts. With a target LC of 92% and a margin of 8%, any LC below 84% - therefore below the expected range- would be deemed unacceptable. In the context of this pragmatic trial, each center will use their own standard of care dose and fractionation regimen; as a general principle, radiotherapy will consist in mild hypofractionation regimen of 5 fractions per week, over 4 to 6&#x02009;weeks. Institutions will not be allowed to change their dose/fractionation once accrual has started. As the study is stratified by participating institution, there will be a balanced number of patients with each dose/fractionation in each arm. In addition, as intensity modulated proton beam therapy is the standard of care for early glottic larynx cancer in some centers, the trial allows the use of proton beam therapy, as long as the same treatment technique is used in each arm.</p><p id="Par116">The delivery of VC-RT will be guided by cautious principles to maximize the safety of treatment delivery which will include: careful definition of tumor extension in collaboration with a head and neck surgeon, use of planning MRI where possible for optimal tumor staging and delineation, use of an ITV for breathing motion, as well as mandatory daily volumetric IGRT. The primary endpoint of the trial will be LC, with secondary endpoints of quality of life (including voice, dysphagia and head and neck symptom burden), toxicity as well as objective measures of voice. If positive, this would result in a paradigm shift in the approach to radiation for treatment early glottic cancers in the institutions where CL-RT remains the standard. On the contrary, if VC-RT demonstrates inferior LC compared to CL-RT, the results of this trial would strengthen the necessity to maintain conservative margins until the possible loopholes in the safety of VC-RT are better understood.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec26"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2021_8195_MOESM1_ESM.docx"><caption><p><bold>Additional file 1.</bold>
</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbrevations</title><def-list><def-item><term>4D-CT</term><def><p id="Par6">Four-dimensional computed tomography</p></def></def-item><def-item><term>BOP-2</term><def><p id="Par7">Bayesian optimal phase 2</p></def></def-item><def-item><term>GRBAS</term><def><p id="Par8">Grade, roughness, breathiness, asthenia, strain</p></def></def-item><def-item><term>CL-RT</term><def><p id="Par9">Complete larynx radiotherapy</p></def></def-item><def-item><term>CT</term><def><p id="Par10">Computed tomography</p></def></def-item><def-item><term>CTCAE</term><def><p id="Par11">Common toxicity criteria for adverse events</p></def></def-item><def-item><term>CTV</term><def><p id="Par12">Clinical target volume</p></def></def-item><def-item><term>DSMB</term><def><p id="Par13">Data safety and monitoring board</p></def></def-item><def-item><term>ECOG</term><def><p id="Par14">Eastern Cooperative Oncology Group</p></def></def-item><def-item><term>GTV</term><def><p id="Par15">Gross tumor volume</p></def></def-item><def-item><term>HNC</term><def><p id="Par16">Head and neck cancer</p></def></def-item><def-item><term>IGRT</term><def><p id="Par17">Image-guided radiotherapy</p></def></def-item><def-item><term>IMRT</term><def><p id="Par18">Intensity modulated radiotherapy</p></def></def-item><def-item><term>IRB </term><def><p id="Par19">Institutional Review Board</p></def></def-item><def-item><term>ITV</term><def><p id="Par20">Internal target volume</p></def></def-item><def-item><term>KM</term><def><p id="Par21">Kaplan meier</p></def></def-item><def-item><term>LC</term><def><p id="Par22">Local control</p></def></def-item><def-item><term>MDADI</term><def><p id="Par23">MD Anderson dysphagia inventory</p></def></def-item><def-item><term>MDASI-HN</term><def><p id="Par24">MD Anderson Symptom inventory- Head and neck module</p></def></def-item><def-item><term>MRI</term><def><p id="Par25">Magnetic resonance imaging</p></def></def-item><def-item><term>OS </term><def><p id="Par26">Overall survival</p></def></def-item><def-item><term>PTV</term><def><p id="Par27">Planning target volume</p></def></def-item><def-item><term>PRV</term><def><p id="Par28">Planning organ at risk volume</p></def></def-item><def-item><term>REB</term><def><p id="Par29">Research Ethics Boar</p></def></def-item><def-item><term>RT</term><def><p id="Par30">Radiotherapy</p></def></def-item><def-item><term>VC-RT </term><def><p id="Par31">Vocal cord radiotherapy</p></def></def-item><def-item><term>VHI-10</term><def><p id="Par32">Voice handicap index-10</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p><sec id="FPar5"><title>Study status</title><p id="Par117">Open and currently accruing.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>HB, DP, DIR, CDF, FN, YY contributed to the conception and design of the protocol, and initial drafting of the protocol. YY contributed to statistical design. KAH, AC, CAN, KF, OB, EF, SPN, LL, JD, HSK contributed to conception and design of the protocol. All authors have read and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar6"><title>Ethics approval and consent to participate</title><p id="Par118">The proposed study has been approved by the Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montreal IRB. Informed written consent to participate in the study will be obtained from participants. The inclusion of Fig. <xref rid="Fig2" ref-type="fig">2</xref> has been approved by our institutional institutional review board.</p></notes><notes id="FPar7"><title>Consent for publication</title><p id="Par119">Not applicable.</p></notes><notes id="FPar8" notes-type="COI-statement"><title>Competing interests</title><p id="Par120">None.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>JSI</given-names></name><name><surname>Ervik</surname><given-names>M</given-names></name><name><surname>Dikshit</surname><given-names>R</given-names></name><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><etal/></person-group><source>GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase no. 11</source><year>2013</year><publisher-loc>Lyon</publisher-loc><publisher-name>International Agency for Research on Cancer</publisher-name></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>2016 CCSsSCoCS</collab></person-group><source>Toronto, Ontario, Canada: Canadian Cancer Society</source><year>2016</year></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>DG</given-names></name><name><surname>Salassa</surname><given-names>JR</given-names></name><name><surname>Hinni</surname><given-names>ML</given-names></name><name><surname>Pearson</surname><given-names>BW</given-names></name><name><surname>Hayden</surname><given-names>RE</given-names></name><name><surname>Perry</surname><given-names>WC</given-names></name></person-group><article-title>Transoral laser microsurgery for carcinoma of the supraglottic larynx</article-title><source>Otolaryngol Head Neck Surg</source><year>2007</year><volume>136</volume><issue>6</issue><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.otohns.2006.12.015</pub-id><?supplied-pmid 17547977?><pub-id pub-id-type="pmid">17547977</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Outzen</surname><given-names>KE</given-names></name><name><surname>Illum</surname><given-names>P</given-names></name></person-group><article-title>CO2-laser therapy for carcinoma of the larynx</article-title><source>J Laryngol Otol</source><year>1995</year><volume>109</volume><issue>2</issue><fpage>111</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1017/S0022215100129421</pub-id><?supplied-pmid 7706914?><pub-id pub-id-type="pmid">7706914</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosch</surname><given-names>P</given-names></name></person-group><article-title>The role of laser microsurgery in the treatment of laryngeal cancer</article-title><source>Curr Opin Otolaryngol Head Neck Surg</source><year>2007</year><volume>15</volume><issue>2</issue><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1097/MOO.0b013e3280147336</pub-id><?supplied-pmid 17413407?><pub-id pub-id-type="pmid">17413407</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cellai</surname><given-names>E</given-names></name><name><surname>Frata</surname><given-names>P</given-names></name><name><surname>Magrini</surname><given-names>SM</given-names></name><name><surname>Paiar</surname><given-names>F</given-names></name><name><surname>Barca</surname><given-names>R</given-names></name><name><surname>Fondelli</surname><given-names>S</given-names></name><name><surname>Polli</surname><given-names>C</given-names></name><name><surname>Livi</surname><given-names>L</given-names></name><name><surname>Bonetti</surname><given-names>B</given-names></name><name><surname>Vitali</surname><given-names>E</given-names></name><name><surname>de Stefani</surname><given-names>A</given-names></name><name><surname>Buglione</surname><given-names>M</given-names></name><name><surname>Biti</surname><given-names>G</given-names></name></person-group><article-title>Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. I. the case of T1N0 disease</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><issue>5</issue><fpage>1378</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.05.018</pub-id><?supplied-pmid 16095847?><pub-id pub-id-type="pmid">16095847</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinshaw</surname><given-names>KA</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Agarwal</surname><given-names>JP</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Havaldar</surname><given-names>R</given-names></name></person-group><article-title>Radiation therapy in T1-T2 glottic carcinoma: influence of various treatment parameters on local control/complications</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2000</year><volume>48</volume><issue>3</issue><fpage>723</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(00)00635-0</pub-id><?supplied-pmid 11020569?><pub-id pub-id-type="pmid">11020569</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>QT</given-names></name><name><surname>Fu</surname><given-names>KK</given-names></name><name><surname>Kroll</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>JK</given-names></name><name><surname>Quivey</surname><given-names>JM</given-names></name><name><surname>Meyler</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1997</year><volume>39</volume><issue>1</issue><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(97)00284-8</pub-id><?supplied-pmid 9300746?><pub-id pub-id-type="pmid">9300746</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell-Burke</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>LJ</given-names></name><name><surname>Goepfert</surname><given-names>H</given-names></name><name><surname>Oswald</surname><given-names>MJ</given-names></name></person-group><article-title>T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>1990</year><volume>116</volume><issue>7</issue><fpage>830</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1001/archotol.1990.01870070078014</pub-id><?supplied-pmid 2363922?><pub-id pub-id-type="pmid">2363922</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laccourreye</surname><given-names>O</given-names></name><name><surname>Laccourreye</surname><given-names>L</given-names></name><name><surname>Garcia</surname><given-names>D</given-names></name><name><surname>Gutierrez-Fonseca</surname><given-names>R</given-names></name><name><surname>Brasnu</surname><given-names>D</given-names></name><name><surname>Weinstein</surname><given-names>G</given-names></name></person-group><article-title>Vertical partial laryngectomy versus supracricoid partial laryngectomy for selected carcinomas of the true vocal cord classified as T2N0</article-title><source>Ann Otol Rhinol LaryngoL</source><year>2000</year><volume>109</volume><issue>10 Pt 1</issue><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1177/000348940010901011</pub-id><?supplied-pmid 11051438?><pub-id pub-id-type="pmid">11051438</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>A</given-names></name><name><surname>Manciocco</surname><given-names>V</given-names></name><name><surname>Simonelli</surname><given-names>M</given-names></name><name><surname>Pagliuca</surname><given-names>G</given-names></name><name><surname>D'Arcangelo</surname><given-names>E</given-names></name><name><surname>de Vincentiis</surname><given-names>M</given-names></name></person-group><article-title>Supracricoid partial laryngectomy in the treatment of laryngeal cancer: univariate and multivariate analysis of prognostic factors</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>2005</year><volume>131</volume><issue>7</issue><fpage>620</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1001/archotol.131.7.620</pub-id><?supplied-pmid 16027286?><pub-id pub-id-type="pmid">16027286</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laccourreye</surname><given-names>O</given-names></name><name><surname>Weinstein</surname><given-names>G</given-names></name><name><surname>Brasnu</surname><given-names>D</given-names></name><name><surname>Trotoux</surname><given-names>J</given-names></name><name><surname>Laccourreye</surname><given-names>H</given-names></name></person-group><article-title>Vertical partial laryngectomy: a critical analysis of local recurrence</article-title><source>Ann Otol Rhinol Laryngol</source><year>1991</year><volume>100</volume><issue>1</issue><fpage>68</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1177/000348949110000111</pub-id><?supplied-pmid 1985529?><pub-id pub-id-type="pmid">1985529</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatani</surname><given-names>M</given-names></name><name><surname>Matayoski</surname><given-names>Y</given-names></name><name><surname>Masaki</surname><given-names>N</given-names></name><name><surname>Teshima</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group><article-title>Radiation therapy for early glottic carcinoma (T1N0M0). The final results of prospective randomized study concerning radiation field</article-title><source>Strahlenther Onkol</source><year>1996</year><volume>172</volume><issue>3</issue><fpage>169</fpage><lpage>172</lpage><?supplied-pmid 8721266?><pub-id pub-id-type="pmid">8721266</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Protocol RTOG 95&#x02013;12 ATea</collab></person-group><source>A randomized study of hyperfractionation versus conventional fractionation in t2 squamous cell carcinoma of the vocal cord</source><year>1996</year></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumsteg</surname><given-names>ZS</given-names></name><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Jaffery</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Gelblum</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Mychalczak</surname><given-names>B</given-names></name><name><surname>Zelefsky</surname><given-names>MJ</given-names></name><name><surname>Wolden</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name></person-group><article-title>Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma</article-title><source>Oral Oncol</source><year>2015</year><volume>51</volume><issue>7</issue><fpage>716</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2015.02.003</pub-id><?supplied-pmid 25958831?><pub-id pub-id-type="pmid">25958831</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>KM</given-names></name><name><surname>Shah</surname><given-names>MD</given-names></name><name><surname>Ogaick</surname><given-names>MJ</given-names></name><name><surname>Enepekides</surname><given-names>D</given-names></name></person-group><article-title>Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy</article-title><source>J Otolaryngology Head Neck Surg</source><year>2009</year><volume>38</volume><issue>6</issue><fpage>603</fpage><lpage>612</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name></person-group><article-title>Laser surgery versus radiotherapy for T1-T2N0 glottic cancer: a meta-analysis</article-title><source>ORL J Otorhinolaryngol Relat Spec</source><year>2011</year><volume>73</volume><issue>6</issue><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1159/000327097</pub-id><?supplied-pmid 22005723?><pub-id pub-id-type="pmid">22005723</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>HL</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Xiong</surname><given-names>JW</given-names></name><name><surname>Yang</surname><given-names>ZL</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name></person-group><article-title>Transoral laser microsurgery versus radiotherapy for T1 glottic carcinoma: a systematic review and meta-analysis</article-title><source>Lasers Med Sci</source><year>2017</year><volume>32</volume><issue>2</issue><fpage>461</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1007/s10103-016-2103-8</pub-id><?supplied-pmid 27966051?><pub-id pub-id-type="pmid">27966051</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J</given-names></name><name><surname>Lacchetti</surname><given-names>C</given-names></name><name><surname>Hammond</surname><given-names>JA</given-names></name><name><surname>Gilbert</surname><given-names>RW</given-names></name></person-group><article-title>Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early (T1) glottic cancer: a systematic review</article-title><source>Head Neck</source><year>2014</year><volume>36</volume><issue>12</issue><fpage>1807</fpage><lpage>1819</lpage><pub-id pub-id-type="doi">10.1002/hed.23504</pub-id><?supplied-pmid 24115131?><pub-id pub-id-type="pmid">24115131</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>L</given-names></name><name><surname>Chudasama</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>CG</given-names></name><name><surname>Loughran</surname><given-names>S</given-names></name><name><surname>McKenzie</surname><given-names>K</given-names></name><name><surname>Wight</surname><given-names>R</given-names></name><etal/></person-group><article-title>Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer</article-title><source>Cochrane Database Syst Rev</source><year>2014</year><volume>12</volume><fpage>Cd002027</fpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdurehim</surname><given-names>Y</given-names></name><name><surname>Hua</surname><given-names>Z</given-names></name><name><surname>Yasin</surname><given-names>Y</given-names></name><name><surname>Xukurhan</surname><given-names>A</given-names></name><name><surname>Imam</surname><given-names>I</given-names></name><name><surname>Yuqin</surname><given-names>F</given-names></name></person-group><article-title>Transoral laser surgery versus radiotherapy: systematic review and meta-analysis for treatment options of T1a glottic cancer</article-title><source>Head Neck.</source><year>2012</year><volume>34</volume><issue>1</issue><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/hed.21686</pub-id><?supplied-pmid 21374753?><pub-id pub-id-type="pmid">21374753</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spielmann</surname><given-names>PM</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>RP</given-names></name></person-group><article-title>Quality of life and functional outcomes in the management of early glottic carcinoma: a systematic review of studies comparing radiotherapy and transoral laser microsurgery</article-title><source>Clin Otolaryngol</source><year>2010</year><volume>35</volume><issue>5</issue><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1111/j.1749-4486.2010.02191.x</pub-id><?supplied-pmid 21108747?><pub-id pub-id-type="pmid">21108747</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>P</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><name><surname>Wight</surname><given-names>R</given-names></name><name><surname>MacKenzie</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name></person-group><article-title>Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer</article-title><source>Cochrane Database Syst Rev</source><year>2002</year><volume>2</volume><fpage>CD002027</fpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendenhall</surname><given-names>WM</given-names></name><name><surname>Werning</surname><given-names>JW</given-names></name><name><surname>Hinerman</surname><given-names>RW</given-names></name><name><surname>Amdur</surname><given-names>RJ</given-names></name><name><surname>Villaret</surname><given-names>DB</given-names></name></person-group><article-title>Management of T1-T2 glottic carcinomas</article-title><source>Cancer.</source><year>2004</year><volume>100</volume><issue>9</issue><fpage>1786</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1002/cncr.20181</pub-id><?supplied-pmid 15112257?><pub-id pub-id-type="pmid">15112257</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smee</surname><given-names>RI</given-names></name><name><surname>Meagher</surname><given-names>NS</given-names></name><name><surname>Williams</surname><given-names>JR</given-names></name><name><surname>Broadley</surname><given-names>K</given-names></name><name><surname>Bridger</surname><given-names>GP</given-names></name></person-group><article-title>Role of radiotherapy in early glottic carcinoma</article-title><source>Head Neck</source><year>2010</year><volume>32</volume><issue>7</issue><fpage>850</fpage><lpage>859</lpage><?supplied-pmid 20029987?><pub-id pub-id-type="pmid">20029987</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinshuck</surname><given-names>AJ</given-names></name><name><surname>Shenoy</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>TM</given-names></name></person-group><article-title>Voice outcomes for early laryngeal cancer</article-title><source>Curr Opin Otolaryngol Head Neck Surg</source><year>2017</year><volume>25</volume><issue>3</issue><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1097/MOO.0000000000000363</pub-id><?supplied-pmid 28277333?><pub-id pub-id-type="pmid">28277333</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greulich</surname><given-names>MT</given-names></name><name><surname>Parker</surname><given-names>NP</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Merati</surname><given-names>AL</given-names></name><name><surname>Misono</surname><given-names>S</given-names></name></person-group><article-title>Voice outcomes following radiation versus laser microsurgery for T1 glottic carcinoma: systematic review and meta-analysis</article-title><source>Otolaryngol Head Neck Surg</source><year>2015</year><volume>152</volume><issue>5</issue><fpage>811</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1177/0194599815577103</pub-id><?supplied-pmid 25837666?><pub-id pub-id-type="pmid">25837666</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>The voice quality after laser surgery versus radiotherapy of T1a glottic carcinoma: systematic review and meta-analysis</article-title><source>Onco Targets Ther</source><year>2017</year><volume>10</volume><fpage>2403</fpage><lpage>2410</lpage><pub-id pub-id-type="doi">10.2147/OTT.S137210</pub-id><?supplied-pmid 28496338?><pub-id pub-id-type="pmid">28496338</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinapoli</surname><given-names>N</given-names></name><name><surname>Parrilla</surname><given-names>C</given-names></name><name><surname>Galli</surname><given-names>J</given-names></name><name><surname>Autorino</surname><given-names>R</given-names></name><name><surname>Micciche</surname><given-names>F</given-names></name><name><surname>Bussu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Multidisciplinary approach in the treatment of T1 glottic cancer. The role of patient preference in a homogenous patient population</article-title><source>Strahlenther Onkol</source><year>2010</year><volume>186</volume><issue>11</issue><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1007/s00066-010-2142-1</pub-id><?supplied-pmid 21069268?><pub-id pub-id-type="pmid">21069268</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loughran</surname><given-names>S</given-names></name><name><surname>Calder</surname><given-names>N</given-names></name><name><surname>MacGregor</surname><given-names>FB</given-names></name><name><surname>Carding</surname><given-names>P</given-names></name><name><surname>MacKenzie</surname><given-names>K</given-names></name></person-group><article-title>Quality of life and voice following endoscopic resection or radiotherapy for early glottic cancer</article-title><source>Clin Otolaryngol</source><year>2005</year><volume>30</volume><issue>1</issue><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2273.2004.00919.x</pub-id><?supplied-pmid 15748189?><pub-id pub-id-type="pmid">15748189</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeckli</surname><given-names>SJ</given-names></name><name><surname>Schnieper</surname><given-names>I</given-names></name><name><surname>Huguenin</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>S</given-names></name></person-group><article-title>Early glottic carcinoma: treatment according patient's preference?</article-title><source>Head Neck</source><year>2003</year><volume>25</volume><issue>12</issue><fpage>1051</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1002/hed.10323</pub-id><?supplied-pmid 14648864?><pub-id pub-id-type="pmid">14648864</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahoor</surname><given-names>T</given-names></name><name><surname>Dawson</surname><given-names>R</given-names></name><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Makura</surname><given-names>Z</given-names></name></person-group><article-title>Transoral laser resection or radiotherapy? Patient choice in the treatment of early laryngeal cancer: a prospective observational cohort study</article-title><source>J Laryngol Otol</source><year>2017</year><volume>131</volume><issue>6</issue><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1017/S0022215116010057</pub-id><?supplied-pmid 28367790?><pub-id pub-id-type="pmid">28367790</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>K</given-names></name><name><surname>Yoo</surname><given-names>J</given-names></name><name><surname>Leeper</surname><given-names>HA</given-names></name><name><surname>Bogue</surname><given-names>B</given-names></name><name><surname>Hawkins</surname><given-names>S</given-names></name><name><surname>Hammond</surname><given-names>JA</given-names></name><name><surname>Gilchrist</surname><given-names>JA</given-names></name><name><surname>Venkatesan</surname><given-names>VM</given-names></name></person-group><article-title>Effects of head and neck radiation therapy on vocal function</article-title><source>J Otolaryngol</source><year>2001</year><volume>30</volume><issue>3</issue><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.2310/7070.2001.20192</pub-id><?supplied-pmid 11771040?><pub-id pub-id-type="pmid">11771040</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjogren</surname><given-names>EV</given-names></name><name><surname>van Rossum</surname><given-names>MA</given-names></name><name><surname>Langeveld</surname><given-names>TP</given-names></name><name><surname>Voerman</surname><given-names>MS</given-names></name><name><surname>van de Kamp</surname><given-names>VA</given-names></name><name><surname>Friebel</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Voice outcome in T1a midcord glottic carcinoma: laser surgery vs radiotherapy</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>2008</year><volume>134</volume><issue>9</issue><fpage>965</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1001/archotol.134.9.965</pub-id><?supplied-pmid 18794442?><pub-id pub-id-type="pmid">18794442</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mamgani</surname><given-names>A</given-names></name><name><surname>Kwa</surname><given-names>SL</given-names></name><name><surname>Tans</surname><given-names>L</given-names></name><name><surname>Moring</surname><given-names>M</given-names></name><name><surname>Fransen</surname><given-names>D</given-names></name><name><surname>Mehilal</surname><given-names>R</given-names></name><etal/></person-group><article-title>Single vocal cord irradiation: image guided intensity modulated Hypofractionated radiation therapy for T1a Glottic Cancer: early clinical results</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2015</year><volume>93</volume><issue>2</issue><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.06.016</pub-id><?supplied-pmid 26264629?><pub-id pub-id-type="pmid">26264629</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>BHJA</given-names></name><name><surname>Grywalski</surname><given-names>C</given-names></name><etal/></person-group><article-title>The voice handi- cap index (VHI) development and validation</article-title><source>Am J Speech- Lang Pat</source><year>1997</year><volume>6</volume><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1044/1058-0360.0603.66</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dornfeld</surname><given-names>K</given-names></name><name><surname>Simmons</surname><given-names>JR</given-names></name><name><surname>Karnell</surname><given-names>L</given-names></name><name><surname>Karnell</surname><given-names>M</given-names></name><name><surname>Funk</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><name><surname>Wacha</surname><given-names>J</given-names></name><name><surname>Zimmerman</surname><given-names>B</given-names></name><name><surname>Buatti</surname><given-names>JM</given-names></name></person-group><article-title>Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>68</volume><issue>3</issue><fpage>750</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.01.047</pub-id><?supplied-pmid 17418971?><pub-id pub-id-type="pmid">17418971</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rancati</surname><given-names>T</given-names></name><name><surname>Schwarz</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>AM</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Popovtzer</surname><given-names>A</given-names></name><name><surname>Mittal</surname><given-names>B</given-names></name><name><surname>Eisbruch</surname><given-names>A</given-names></name></person-group><article-title>Radiation dose-volume effects in the larynx and pharynx</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>76</volume><issue>3 Suppl</issue><fpage>S64</fpage><lpage>S69</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.03.079</pub-id><?supplied-pmid 20171520?><pub-id pub-id-type="pmid">20171520</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanguineti</surname><given-names>G</given-names></name><name><surname>Adapala</surname><given-names>P</given-names></name><name><surname>Endres</surname><given-names>EJ</given-names></name><name><surname>Brack</surname><given-names>C</given-names></name><name><surname>Fiorino</surname><given-names>C</given-names></name><name><surname>Sormani</surname><given-names>MP</given-names></name><name><surname>Parker</surname><given-names>B</given-names></name></person-group><article-title>Dosimetric predictors of laryngeal edema</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>68</volume><issue>3</issue><fpage>741</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.01.010</pub-id><?supplied-pmid 17398024?><pub-id pub-id-type="pmid">17398024</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plummer</surname><given-names>C</given-names></name><name><surname>Henderson</surname><given-names>RD</given-names></name><name><surname>O'Sullivan</surname><given-names>JD</given-names></name><name><surname>Read</surname><given-names>SJ</given-names></name></person-group><article-title>Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review</article-title><source>Stroke</source><year>2011</year><volume>42</volume><issue>9</issue><fpage>2410</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.111.615203</pub-id><?supplied-pmid 21817150?><pub-id pub-id-type="pmid">21817150</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorresteijn</surname><given-names>LD</given-names></name><name><surname>Kappelle</surname><given-names>AC</given-names></name><name><surname>Scholz</surname><given-names>NM</given-names></name><name><surname>Munneke</surname><given-names>M</given-names></name><name><surname>Scholma</surname><given-names>JT</given-names></name><name><surname>Balm</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Increased carotid wall thickening after radiotherapy on the neck</article-title><source>Eur J Cancer</source><year>2005</year><volume>41</volume><issue>7</issue><fpage>1026</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2005.01.020</pub-id><?supplied-pmid 15862751?><pub-id pub-id-type="pmid">15862751</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swisher-McClure</surname><given-names>S</given-names></name><name><surname>Mitra</surname><given-names>N</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Ahn</surname><given-names>P</given-names></name><name><surname>Wan</surname><given-names>F</given-names></name><name><surname>O'Malley</surname><given-names>B</given-names></name><name><surname>Weinstein</surname><given-names>GS</given-names></name><name><surname>Bekelman</surname><given-names>JE</given-names></name></person-group><article-title>Risk of fatal cerebrovascular accidents after external beam radiation therapy for early-stage glottic laryngeal cancer</article-title><source>Head Neck</source><year>2014</year><volume>36</volume><issue>5</issue><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1002/hed.23342</pub-id><?supplied-pmid 23595858?><pub-id pub-id-type="pmid">23595858</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Buckley</surname><given-names>AR</given-names></name><name><surname>Graeb</surname><given-names>D</given-names></name><name><surname>Walman</surname><given-names>B</given-names></name><name><surname>Salvian</surname><given-names>A</given-names></name><name><surname>Hay</surname><given-names>JH</given-names></name></person-group><article-title>Carotid artery stenosis in asymptomatic patients who have received unilateral head-and-neck irradiation</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><issue>4</issue><fpage>1197</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.04.017</pub-id><?supplied-pmid 15978738?><pub-id pub-id-type="pmid">15978738</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulholland</surname><given-names>GB</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Tkacyzk</surname><given-names>N</given-names></name><name><surname>Seikaly</surname><given-names>H</given-names></name><name><surname>O'Connell</surname><given-names>D</given-names></name><etal/></person-group><article-title>Optimal detection of hypothyroidism in early stage laryngeal cancer treated with radiotherapy</article-title><source>J Otolaryngol Head Neck Surg</source><year>2015</year><volume>44</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s40463-015-0085-3</pub-id><pub-id pub-id-type="pmid">26362315</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendenhall</surname><given-names>WM</given-names></name><name><surname>Amdur</surname><given-names>RJ</given-names></name><name><surname>Morris</surname><given-names>CG</given-names></name><name><surname>Hinerman</surname><given-names>RW</given-names></name></person-group><article-title>T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><issue>20</issue><fpage>4029</fpage><lpage>4036</lpage><pub-id pub-id-type="doi">10.1200/JCO.2001.19.20.4029</pub-id><?supplied-pmid 11600604?><pub-id pub-id-type="pmid">11600604</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>AS</given-names></name><name><surname>Fish</surname><given-names>B</given-names></name><name><surname>Fenton</surname><given-names>JE</given-names></name><name><surname>Husband</surname><given-names>DJ</given-names></name></person-group><article-title>The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation?</article-title><source>Head Neck</source><year>2004</year><volume>26</volume><issue>2</issue><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1002/hed.10361</pub-id><?supplied-pmid 14762881?><pub-id pub-id-type="pmid">14762881</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Rudoltz</surname><given-names>MS</given-names></name><name><surname>Canady</surname><given-names>DJ</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Machtay</surname><given-names>M</given-names></name><name><surname>Pittard</surname><given-names>MQ</given-names></name><etal/></person-group><article-title>Second malignant neoplasia in patients with T1 glottic cancer treated with radiation</article-title><source>Laryngoscope</source><year>1998</year><volume>108</volume><issue>12</issue><fpage>1853</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1097/00005537-199812000-00016</pub-id><?supplied-pmid 9851503?><pub-id pub-id-type="pmid">9851503</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>DI</given-names></name><name><surname>Fuller</surname><given-names>CD</given-names></name><name><surname>Barker</surname><given-names>JL</given-names><suffix>Jr</suffix></name><name><surname>Mason</surname><given-names>B</given-names></name><name><surname>Garcia</surname><given-names>JA</given-names></name><name><surname>Lewin</surname><given-names>JS</given-names></name><name><surname>Holsinger</surname><given-names>FC</given-names></name><name><surname>Stasney</surname><given-names>CR</given-names></name><name><surname>Frank</surname><given-names>SJ</given-names></name><name><surname>Schwartz</surname><given-names>DL</given-names></name><name><surname>Morrison</surname><given-names>WH</given-names></name><name><surname>Garden</surname><given-names>AS</given-names></name><name><surname>Ang</surname><given-names>KK</given-names></name></person-group><article-title>Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>77</volume><issue>2</issue><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.04.061</pub-id><?supplied-pmid 19679406?><pub-id pub-id-type="pmid">19679406</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chera</surname><given-names>BS</given-names></name><name><surname>Amdur</surname><given-names>RJ</given-names></name><name><surname>Morris</surname><given-names>CG</given-names></name><name><surname>Mendenhall</surname><given-names>WM</given-names></name></person-group><article-title>Carotid-sparing intensity-modulated radiotherapy for early-stage squamous cell carcinoma of the true vocal cord</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>77</volume><issue>5</issue><fpage>1380</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.07.1687</pub-id><?supplied-pmid 19942356?><pub-id pub-id-type="pmid">19942356</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Bahig HN-T, Nguyen-Tan PF, Filion, E.; Roberge, D.; Thanomsack, P.; de Guise, Jacques.; Blais D,; Doucet R.; L Etourneau-Guillon L.; Lambert, L. Larynx motion considerations in partial larynx volumetric modulated arc therapy for early glottic cancer. J Med Imaging Radiat Oncol. 2017.</mixed-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>RJ</given-names></name><name><surname>Kendall</surname><given-names>KA</given-names></name><name><surname>McKenzie</surname><given-names>S</given-names></name><name><surname>Goncalves</surname><given-names>MI</given-names></name><name><surname>Walker</surname><given-names>A</given-names></name></person-group><article-title>Structural displacements in normal swallowing: a videofluoroscopic study</article-title><source>Dysphagia.</source><year>2000</year><volume>15</volume><issue>3</issue><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1007/s004550010017</pub-id><?supplied-pmid 10839828?><pub-id pub-id-type="pmid">10839828</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantas</surname><given-names>RO</given-names></name><name><surname>Kern</surname><given-names>MK</given-names></name><name><surname>Massey</surname><given-names>BT</given-names></name><name><surname>Dodds</surname><given-names>WJ</given-names></name><name><surname>Kahrilas</surname><given-names>PJ</given-names></name><name><surname>Brasseur</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Effect of swallowed bolus variables on oral and pharyngeal phases of swallowing</article-title><source>Am J Phys</source><year>1990</year><volume>258</volume><issue>5 Pt 1</issue><fpage>G675</fpage><lpage>G681</lpage></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamlet</surname><given-names>S</given-names></name><name><surname>Ezzell</surname><given-names>G</given-names></name><name><surname>Aref</surname><given-names>A</given-names></name></person-group><article-title>Larynx motion associated with swallowing during radiation therapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1994</year><volume>28</volume><issue>2</issue><fpage>467</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/0360-3016(94)90073-6</pub-id><?supplied-pmid 8276663?><pub-id pub-id-type="pmid">8276663</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>JA</given-names></name><name><surname>Paulson</surname><given-names>ES</given-names></name><name><surname>Ahunbay</surname><given-names>E</given-names></name><name><surname>Schultz</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>XA</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>Dynamic MRI analysis of tumor and organ motion during rest and deglutition and margin assessment for radiotherapy of head-and-neck cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>81</volume><issue>5</issue><fpage>e803</fpage><lpage>e812</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.12.015</pub-id><?supplied-pmid 21300480?><pub-id pub-id-type="pmid">21300480</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Asselen</surname><given-names>B</given-names></name><name><surname>Raaijmakers</surname><given-names>CP</given-names></name><name><surname>Lagendijk</surname><given-names>JJ</given-names></name><name><surname>Terhaard</surname><given-names>CH</given-names></name></person-group><article-title>Intrafraction motions of the larynx during radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2003</year><volume>56</volume><issue>2</issue><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(02)04572-8</pub-id><?supplied-pmid 12738313?><pub-id pub-id-type="pmid">12738313</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>JD</given-names></name><name><surname>Hope</surname><given-names>A</given-names></name><name><surname>El Naqa</surname><given-names>I</given-names></name><name><surname>Apte</surname><given-names>A</given-names></name><name><surname>Lindsay</surname><given-names>PE</given-names></name><name><surname>Bosch</surname><given-names>W</given-names></name><etal/></person-group><article-title>A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>69</volume><issue>4</issue><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.04.077</pub-id><?supplied-pmid 17689035?><pub-id pub-id-type="pmid">17689035</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangsaas</surname><given-names>A</given-names></name><name><surname>Astreinidou</surname><given-names>E</given-names></name><name><surname>Quint</surname><given-names>S</given-names></name><name><surname>Levendag</surname><given-names>PC</given-names></name><name><surname>Heijmen</surname><given-names>B</given-names></name></person-group><article-title>Cone-beam computed tomography-guided positioning of laryngeal cancer patients with large interfraction time trends in setup and nonrigid anatomy variations</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2013</year><volume>87</volume><issue>2</issue><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.06.2032</pub-id><?supplied-pmid 23958149?><pub-id pub-id-type="pmid">23958149</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>SO</given-names></name><name><surname>Astreinidou</surname><given-names>E</given-names></name><name><surname>Levendag</surname><given-names>PC</given-names></name><name><surname>Heijmen</surname><given-names>BJ</given-names></name></person-group><article-title>Impact of geometric variations on delivered dose in highly focused single vocal cord IMRT</article-title><source>Acta Oncol</source><year>2014</year><volume>53</volume><issue>2</issue><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.3109/0284186X.2013.812793</pub-id><?supplied-pmid 23879644?><pub-id pub-id-type="pmid">23879644</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>SO</given-names></name><name><surname>Astreinidou</surname><given-names>E</given-names></name><name><surname>de Boer</surname><given-names>HC</given-names></name><name><surname>Keskin-Cambay</surname><given-names>F</given-names></name><name><surname>Breedveld</surname><given-names>S</given-names></name><name><surname>Voet</surname><given-names>P</given-names></name><etal/></person-group><article-title>IMRT for image-guided single vocal cord irradiation</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>82</volume><issue>2</issue><fpage>989</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.12.022</pub-id><?supplied-pmid 21300449?><pub-id pub-id-type="pmid">21300449</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levendag</surname><given-names>PC</given-names></name><name><surname>Teguh</surname><given-names>DN</given-names></name><name><surname>Keskin-Cambay</surname><given-names>F</given-names></name><name><surname>Al-Mamgani</surname><given-names>A</given-names></name><name><surname>van Rooij</surname><given-names>P</given-names></name><name><surname>Astreinidou</surname><given-names>E</given-names></name><etal/></person-group><article-title>Single vocal cord irradiation: a competitive treatment strategy in early glottic cancer</article-title><source>Radiother Oncol.</source><year>2011</year><volume>101</volume><issue>3</issue><fpage>415</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2011.05.026</pub-id><?supplied-pmid 21663989?><pub-id pub-id-type="pmid">21663989</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>CL</given-names></name><name><surname>Steenbakkers</surname><given-names>RJ</given-names></name><name><surname>Bourhis</surname><given-names>J</given-names></name><name><surname>Budach</surname><given-names>W</given-names></name><name><surname>Grau</surname><given-names>C</given-names></name><name><surname>Gregoire</surname><given-names>V</given-names></name><etal/></person-group><article-title>CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG oncology and TROG consensus guidelines</article-title><source>Radiother Oncol</source><year>2015</year><volume>117</volume><issue>1</issue><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2015.07.041</pub-id><?supplied-pmid 26277855?><pub-id pub-id-type="pmid">26277855</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints</article-title><source>Stat Med</source><year>2017</year><volume>36</volume><issue>21</issue><fpage>3302</fpage><lpage>3314</lpage><pub-id pub-id-type="doi">10.1002/sim.7338</pub-id><?supplied-pmid 28589563?><pub-id pub-id-type="pmid">28589563</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gelman AaH</surname><given-names>J</given-names></name></person-group><source>Data analysis using regression and multilevel/hierarchical models</source><year>2007</year><publisher-loc>Cambridge</publisher-loc><publisher-name>Cambridge University Press</publisher-name></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McCullagh PaN</surname><given-names>JA</given-names></name></person-group><source>Generalized linear models</source><year>1989</year><publisher-loc>New York</publisher-loc><publisher-name>Chapman and Hall/CRC Press</publisher-name></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>DJ</given-names></name><name><surname>Timmerman</surname><given-names>RD</given-names></name><name><surname>Nedzi</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>NL</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>BD</given-names></name></person-group><article-title>Phase 1 fractional dose-escalation study of equipotent stereotactic radiation therapy regimens for early-stage Glottic larynx Cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2019</year><volume>105</volume><issue>1</issue><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2019.03.010</pub-id><?supplied-pmid 30880269?><pub-id pub-id-type="pmid">30880269</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucha-Malecka</surname><given-names>A</given-names></name><name><surname>Chrostowska</surname><given-names>A</given-names></name><name><surname>Urbanek</surname><given-names>K</given-names></name><name><surname>Malecki</surname><given-names>K</given-names></name></person-group><article-title>Prognostic factors in patients with T1 glottic cancer treated with radiotherapy</article-title><source>Strahlenther Onkol</source><year>2019</year><volume>195</volume><issue>9</issue><fpage>792</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1007/s00066-019-01481-2</pub-id><?supplied-pmid 31214734?><pub-id pub-id-type="pmid">31214734</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohynska</surname><given-names>R</given-names></name><name><surname>Slavicek</surname><given-names>A</given-names></name><name><surname>Bahanan</surname><given-names>A</given-names></name><name><surname>Novakova</surname><given-names>P</given-names></name></person-group><article-title>Predictors of local failure in early laryngeal cancer</article-title><source>Neoplasma.</source><year>2005</year><volume>52</volume><issue>6</issue><fpage>483</fpage><lpage>488</lpage><?supplied-pmid 16284693?><pub-id pub-id-type="pmid">16284693</pub-id></element-citation></ref></ref-list></back></article>